|
Volumn 7, Issue 9, 2017, Pages
|
Clinical trial transparency: A reassessment of industry compliance with clinical trial registration and reporting requirements in the United States
|
Author keywords
clinical trials; ethics (see medical ethics); health policy; law (see medical law); public health
|
Indexed keywords
AFLIBERCEPT;
APIXABAN;
AXITINIB;
BEDAQUILINE;
BOSUTINIB;
COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
HAEMOPHILUS INFLUENZAE TYPE B MENINGOCOCCUS TETANUS VACCINE;
PASIREOTIDE;
PERTUZUMAB;
REGORAFENIB;
TAFLUPROST;
TALIGLUCERASE ALFA;
TERIFLUNOMIDE;
TOFACITINIB;
VISMODEGIB;
ARTICLE;
CLINICAL PROTOCOL;
CLINICAL RESEARCH;
CLINICAL TRIAL (TOPIC);
CROSS-SECTIONAL STUDY;
DATA ANALYSIS;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG LEGISLATION;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
OUTCOME ASSESSMENT;
PROTOCOL COMPLIANCE;
UNITED STATES;
ACCESS TO INFORMATION;
INTERPERSONAL COMMUNICATION;
LEGISLATION AND JURISPRUDENCE;
REGISTER;
STATISTICS AND NUMERICAL DATA;
ACCESS TO INFORMATION;
CLINICAL TRIALS AS TOPIC;
CROSS-SECTIONAL STUDIES;
DISCLOSURE;
DRUG APPROVAL;
DRUG INDUSTRY;
HUMANS;
REGISTRIES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
EID: 85029850050
PISSN: None
EISSN: 20446055
Source Type: Journal
DOI: 10.1136/bmjopen-2016-015110 Document Type: Article |
Times cited : (34)
|
References (16)
|